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INTRODUCTION
Cisplatin is a major anti-neoplastic drug for the treatment
of solid tumors, but dose-dependent renal toxicity limits the
use of optimal doses of this drug. Cisplatin has intracellular
toxic effects on proximal straight and distal convoluted tu-
bules. And DNA damage, oxidative stress, apoptosis, and
inflammation have been implicated in the pathogenesis of
cisplatin-induced renal injury (1). 
Recent studies have shown increased tissue content of in-
flammatory mediators together with inflammatory cell infil-
tration, suggesting that inflammation plays an important role
in cisplatin-induced renal injury (2, 3). Although the precise
inflammatory mechanisms are unknown, marked attenuation
of cisplantin-induced renal damage by inhibition of TNF-a
indicates that TNF-ahas a central role in mediating cisplatin-
induced inflammatory renal injury (4). 
Apoptosis is generally linked to the stepwise activation of
a set of proteolytic enzymes called caspases. Several mecha-
nisms that activate caspases 8 and 9 or executioner caspase
3 are all known to be involved in cisplatin-induced tubular
cell apoptosis and caspase inhibition markedly reduces kid-
ney injury (5, 6). 
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of lig-
and-dependent transcription factors known to be critical in
regulating diverse biological processes, such as lipid meta-
bolism, adipogenesis, insulin sensitivity, immune response,
cell growth, and differentiation (7-10). Recently, the reno-
protective actions of ligands for PPARg, such as thiazolidine-
diones (TZD), have been reported. Although activation of a
PPARg in inducing renal tubular cell apoptosis has also been
suggested, Lee et al. (11) reported that the PPARg agonist,
rosiglitazone, has renoprotective activity by reducing NF-kB
phosphorylation and TNF-a production in cisplatin-induced
renal damage. Recent observations have suggested that in
addition to inhibiting inflammatory cytokine production,
IL-10 is also important in mediating a tissue protective effect
of PPARg activation in several other injury models (12, 13).
In addition, IL-10 has been known to inhibit inflammato-
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IL-10 Mediates Rosiglitazone-Induced Kidney Protection in Cisplatin
Nephrotoxicity
Cisplatin, a major anti-neoplastic drug, is known to be nephrotoxic and inflammation-
inducing. A peroxisome proliferator-activated receptor gamma agonist, regulating
lipid metabolism, has known to have anti-inflammatory effect, but the protection mech-
anisms in various kidney injuries are not fully understood. The purpose of this study
was to examine the reno-protective effect of rosiglitazone on cisplatin nephrotoxicity
in mice focusing on inflammation and apoptosis. Male BALB/c mice were pretreated
with rosiglitazone (10 mg/kg) or vehicle through daily intraperitoneal injection for 3
days and then were given a single injection of cisplatin (20 mg/kg). Cisplatin induced
a significant rise in blood urea nitrogen and creatinine levels, and tubular cell dam-
age with marked tissue inflammation. Tissue cytokines and chemokines measured
by a cytometric bead array showed increased TNF-a, IL-6, MCP-1, and IFN-g levels,
while IL-10, an anti-inflammatory cytokine, was significantly decreased by cisplatin
treatment. However, rosiglitazone pretreatment substantially reversed the depressed
IL-10 level with simultaneous suppression of proinflammatory cytokines and chemo-
kines. This tissue cytokine and chemokine milieu was associated with marked atten-
uation of kidney injury elicited by cisplatin. These findings suggest that the rosigli-
tazone-mediated renoprotective effect in cisplatin nephrotoxicity of mice is partially
mediated by upregulation of anti-inflammatory IL-10 production.
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nephrotoxicity (14). However, whether the protective effect
of rosiglitazone, a PPARg agonist, in ciplatin nephrotoxici-
ty is IL-10-dependent has not been clearly demonstrated. In
this study, we investigated the effect of a PPARg agonist in
a cisplatin-induced AKI mouse model, with a focus on inflam-
mation and apoptosis. 
MATERIALS AND METHODS
Animals and drugs
Male BALB/c mice (20-25 g), purchased from Orient (Char-
les River Korea, Seoul, Korea), had free access to water and
chow before experiment. Animal care followed the criteria
of the Animal Care Committee of Korea University for the
use of laboratory animals in research. Cisplatin (Sigma-Ald-
rich, St. Louis, MO, USA) was diluted in normal saline to a
final concentration of 2 mg/mL. And mice were given a sin-
gle intraperitoneal injection of cisplatin (20 mg/kg), while
control animals received the same volume of normal saline.
To investigate the renoprotective effect of rosiglitazone, ano-
ther group of mice were pretreated with rosiglitazone (10 mg/
kg; Alexis Biochemicals, Lausen, Switzerland) or the same
volume of vehicle (0.1% dimethyl sulfoxide [DMSO] in nor-
mal saline) through daily intraperitoneal injections for 3 days
before cisplatin injection. Mice were sacrificed at 4, 24, 48,
and 72 hr after cisplatin administration. Blood was collect-
ed by intracardiac puncture and both kidneys were processed
for histologic examination, RNA and protein isolation. 
Biochemical analysis and histologic examination 
Blood urea nitrogen (BUN) and creatinine levels were mea-
sured using a Hitachi 747 automatic analyzer. Renal tissue
samples were fixed in 4% buffered paraformaldehyde and
embedded in paraffin. After deparraffinization, 5 mm sections
were processed and stained with periodic acid-Schiff (PAS).
Tubular damage was estimated by examining 8-10 high power
fields (HPF; ×200) per section by using a scoring system
based on the percentage of damaged tubules per field (1, <25%;
2, 25% to 50%; 3, 50% to 75%; and 4, >75%). The mean
score of each animal was compared. For the immunohisto-
chemical detection of monocytes and macrophages, we stain-
ed formalin-fixed and paraffin-embedded kidney sections
with monoclonal antibody against F4/80 (Serotec, Oxford,
UK). After deparaffinization, endogeneous peroxidase activ-
ity was blocked with 0.5% hydrogen peroxidase. Sections
were blocked for 10 min with goat serum, followed by incu-
bation with primary antibody for 1 hr at room temperature
(1:100). Specific labeling was detected with a biotin-conju-
gated goat anti-rat immunoglobulin G and an avidin-biotin
peroxidase complex (Vector Laboratories, Burlingame, CA,
USA). Naphthol AS-D chloroacetate (Sigma-Aldrich) was
used to identify neutrophils. Eight to 10 HPFs were captured
and the mean number of esterase-positive cells in the field
was calculated in order for quantification.
Detection of apoptosis
Detection of apoptotic cells in the kidney was performed
in paraffin-embedded kidney tissue sections using an Apop-
TagPlus (Intergen, Purchase, NY, USA) following the man-
ufacturer’s protocol. The number of apoptotic cells in the
outer medulla was semiquantitatively measured by count-
ing 8-10 HPF (×200) per section.
Quantification of cytokines and chemokine by cytometric
bead array
Quantification of various cytokines and chemokine in kid-
ney tissues was done using cytometric bead array. A mouse
inflammation kit (BD Biosciences, San Diego, CA, USA)
was used according to the manufacturer’s instructions to simul-
taneously detect mouse IL-12p70, TNF-a, IFN-g, MCP-1,
IL-10, and IL-6, as previously described (15). Briefly, a mix-
ture of 6 capture bead populations (50 mL) with distinct flu-
orescence intensities (detected in FL3) coated with antibod-
ies specific for the above cytokines and chemokine was mixed
with each sample from kidney homogenates/standard (50 mL).
Standard dilutions and test samples were added to the appro-
priate sample tubes (50 mL/tube). Additionally, PE-conjugat-
ed detection antibodies (detected in FL-2; 50 mL) were added
to form sandwich complexes. After 2 hr of incubation at room
temperature, the samples were washed with 1 mL of wash
buffer and centrifuged (200 g for 5 min). Three hundred mL
of wash buffer was added to each assay tube before acquisi-
tion in a FACScan flow cytometer (FACSCaliburTM; BD Bio-
sciences) and the sample results were analyzed using CBA
software (BD Biosciences). The concentration for each cyto-
kine in cell supernatants was determined by interpolation
from the corresponding standard curve and normalized accord-
ing to protein concentrations. The range of detection was 20-
5,000 pg/mL for each cytokine.
Measurement of caspase activity
The activities of caspases 3, 8, and 9 in kidney tissues were
determined by fluorometric detection of free 7-amino-4-tri-
fluoromethylcoumarin (AFC; caspases 3 and 8) or 7-amino-
4-methylcoumarin (AMC; caspase 9), following the manufac-
turer’s protocol (ApoAlertTM‚ Caspase Fluorescent Assay Kits;
BD Biosciences, Palo Alto, CA, USA) by using a SynergyTM
HT Multi-Detection Microplate Reader (Biotek, Woburn,
MA, USA). Briefly, kidney tissues were homogenized in 1 mL
of lysis buffer, incubated on ice for 10 min and centrifuged
at 15,000 g for 10 min at 4℃. Supernatant containing 500
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of reaction buffer, 1 mM/L dithiothreitol (DTT), and 50 mM/
L AMC or AFC substrate conjugates. The fluorescence was
read at 400/505 (excitation/emission) nm for caspases 3 and
8 and 380/460 nm for caspase 9 and the samples were run in
triplicate. The activity of the caspases was expressed as the
percent increase compared to the saline-treated control group
and samples which had caspase inhibitors served as negative
controls.
Statistical analysis
All data are presented as the mean±SE and were analyzed
by a Student t-test. A P value <0.05 was considered statisti-
cally significant.
RESULTS
Effect of rosiglitazone on kidney injury following cisplatin
administration
Renal function was assessed at 4, 24, and 72 hr and histo-
logic kidney damage was compared at 72 hr. As shown in
Fig. 1, cisplatin injection significantly increased BUN and
creatinine levels. In contrast, rosiglitazone pretreatment sig-
nificantly reduced the increase of BUN and creatinine; his-
tologic damage was less severe at 72 hr (Figs. 1, 2). Cisplatin
caused renal damage with loss of the brush border, necrosis
of tubular cells, cast formation. Rosiglitazone pretreatment
significantly reduced these changes with improvement of the
tubular injury score (Fig. 2). 
Effect of rosiglitazone on cytokine and chemokine
expression and inflammation
We investigated the effect of rosiglitazone on kidney cyto-
kine and chemokine protein expression by CBA. Proinflam-
matory cytokines (TNF-a, IL-6, and IFN-g) and chemokine
(MCP-1) all increased significantly in cisplatin-treated ani-
mals at 24 hr. Rosiglitazone pretreatment attenuated these
changes. In contrast to these proinflammatory mediators, IL-
10, a potent anti-inflamamtory cytokine was significantly
decreased in cisplatin-treated kidneys compared to sham. In
rosiglitazone-pretreated kidneys, the kidney IL-10 protein
level increased significantly. At 24 hr after cisplatin admin-
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Fig. 1. Effect of rosiglitazone on renal function in cisplatin-induced ARF in mice. Vehicle (0.1% DMSO) or rosiglitazone (rosi) were injected
intraperitoneally for 3 days before cisplatin (cis) administration. Blood urea nitrogen (BUN) and creatinine (Cr) were measured at 4, 24, and
72 hr (n=5 animals per group). *P<0.05 vs. control, 
� P<0.05 vs. vehicle+cisplatin.
C, control; R, rosiglitazone.
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Fig. 2. Effect of rosiglitazone on renal histology in cisplatin-induced renal injury in mice. Renal histology was examined at 72 hr after
cisplatin injection. Semiquantitative assessment of renal damage was scored as described in the Method section. (A) Vehicle+cisplatin
(vehicle/cis), (B) Rosiglitazone+cisplatin (rosi/cis), (C) Semiquantitative histologic injury score. (A, B) Periodic acid-Schiff (PAS) ×200
(n=9 animals per group). *P<0.05 vs. vehicle+cisplatin. 
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Rosi/cisistration, renal function and histologic damage of the kidney
was not apparent. Increased IL-10 production by rosiglita-
zone pretreatment was considered responsible for subsequent
protection at 72 hr (Fig. 3). By immunohistochemical stain-
ing of kidney macrophages and neutrophils, kidney macro-
phages (F4/80 positive cells) and neutrophils (esterase-posi-
tive cells) increased markedly in cisplatin-treated kidneys;
and rosiglitazone pretreatment also significantly reduced infil-
tration of these cells (Figs. 4, 5).
Effect of rosiglitazone on caspase activation and apoptosis
The effect of rosiglitazone on activation of different types
of caspases and resulting apoptosis was examined. Activities
of caspases 8, 9, and 3 in kidney tissues were measured and
tubular cell apoptosis was assessed. The activity of caspase 3
increased significantly and rosiglitazone pretreatment atten-
uated the activation of caspase 3 at 24 and 72 hr. However,
caspase 8 and 9 showed a low degree of activation following
cisplatin administration, and rosiglitazone pretreatment did
not have any effect on their activities (Fig. 6). This result sug-
gested that caspase 3 were activated independent from cas-
pase 8 or 9 by cisplatin and that caspase 3 was directly inhib-
ited by rosiglitazone. We also performed TUNEL staining
for quantifying renal tubular cell apoptosis and observed that
increased tubular cell apoptosis by cisplatin were significantly
attenuated by rosiglitazone pretreatment at 48 and 72 hr
(Fig. 7). 
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Fig. 3. Effect of rosiglitazone on cytokines/chemokine expression in cisplatin-induced renal injury in mice. Inflammatory cytokines and MCP-1
was quantified at 24 and 48 hr after injection of vehicle+cisplatin (vehicle/cis) or rosiglitazone+cisplatin (rosi/cis) by cytometric bead array.
In each experiment, data are presented as mean±SE (n=9 animals per group). *P<0.05 vs. control; 
� P<0.05 vs. vehicle+cisplatin.
C, control; R, rosiglitazone.
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Fig. 4. Effect of rosiglitazone on esterase positive cells infiltration in cisplatin-induced renal injury in mice. Eight to ten ×200 fields were count-
ed and mean numbers of esterase positive leukocytes were compared at 72 hr after cisplatin administration. (A) Vehicle+cisplatin (vehi-
cle/cis), (B) Rosiglitazone+cisplatin (rosi/cis), (C) Mean number of esterase positive cells (n=9 animals per group). *P<0.05 vs. vehicle+cis-
platin.
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Fig. 5. Effect of rosiglitazone on F4/80 positive cells infiltration in cisplatin-induced renal injury in mice. Eight to ten ×200 fields were counted
and mean numbers of F4/80 positive leukocytes were compared at 72 hr after cisplatin administration. (A) Vehicle+cisplatin (vehicle/cis),
(B) Rosiglitazone+cisplatin (rosi/cis), (C) Mean numbers of F4/80 positive cells (n=9 animals per group). *P<0.05 vs. vehicle+cisplatin.
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Fig. 6. Effect of rosiglitazone on the activation of caspases in cis-
platin-induced renal injury in mice. Tissue caspase activities were
measured at 4, 24, and 72 hr and were expressed as percent in-
crease compared to saline treated control group. (A) Caspase 3
activity, (B) Caspase 8 activity, (C) Caspase 9 activity (n=9 animals
per group). *P<0.05 vs. control, 
� P<0.05 vs. vehicle+cisplatin.
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Fig. 7. Effect of rosiglitazone on apoptosis in cisplatin-induced renal injury in mice. Detection of apoptosis was done at 48 hr after cisplatin
administration. (A) Vehicle+cisplatin (vehicle/cis), (B) Rosiglitazone+cisplatin (rosi/cis), (C) Mean numbers of TUNEL positive cells were
counted in eight to ten high power field. (A, B) TUNEL stain ×200 (n=9 animals per group). *P<0.05 vs. control, 
� P<0.05 vs. vehicle+cis-
platin.
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*DISCUSSION
In the present study, we demonstrated that pretreatment
with the PPARg agonist, rosiglitazone, attenuated cisplatin-
induced kidney injury by reducing tissue inflammation and
apoptosis. More importantly, rosiglitazone pretreatment in-
creased the kidney IL-10 level at 24 hr, and this change was
accompanied by decreased inflammation and cytotoxicity at
72 hr after cisplatin administration. Rosiglitazone also dec-
reased cisplatin-induced tubular cell apoptosis by directly
inhibiting caspase 3 activation. 
Cisplatin, a major anti-neoplastic drug of solid tumors, has
multiple intracellular effects, such as direct toxicity with reac-
tive oxygen species, by activating mitogen activated protein
kinases (MAPKinase), by inducing apoptosis, and by stim-
ulating inflammation and fibrogenesis (1). Many potential
therapeutic approaches targeting these steps for the preven-
tion of cisplatin-induced renal injury has been extensively
studied. In particular, recent evidence indicates that inflam-
mation has an important role in the pathogenesis of cisplatin-
induced renal injury. Ramesh et al. (4) demonstrated that
TNF-a played a central role in the activation of various cyto-
kines. They showed the beneficial effect of high dose salicy-
late was mediated by its anti-inflammatory effect in attenu-
ating TNF-a production through reducing NF-kB transcrip-
tion (16). The role of inflammation in cisplatin nephrotoxi-
city has also been confirmed by showing the protective effect
of exogenous administered anti-inflammatory cytokine IL-
10 (14). In our study, we also showed cisplatin evoked sub-
stantial tissue inflammation with upregulation of various
inflammatory mediators. Unlike other studies that demon-
strated transcriptional upregulation of inflammatory media-
tors, we measured tissue protein levels of various cytokines
and chemokines early after cisplatin administration and ob-
served that in addition to TNF-a, other cytokines, such as
IFN-g and IL-6, and the chemokine, MCP-1, are markedly
increased in cisplatin-treated kidneys. In contrast to proin-
flammatory mediators, however, the IL-10 protein level dec-
reased markedly in cisplatin-treated kidneys. These findings
suggested that decreased endogenous IL-10 release might con-
tribute to enhanced inflammation and subsequent tissue injury
by cisplatin, because IL-10 is a well-known anti-inflamma-
tory cytokine that has been known to suppress proinflamma-
tory cytokines and chemokines. Rosiglitazone pretreatment,
however, in contrast to cisplatin-treated kidneys, substantially
improved endogenous IL-10 release with simultaneous sup-
pression of TNF-a, IL-6, MCP-1, and IFN-g. Rosiglitazone
is a PPARg agonist that has been reported to have an anti-
inflammatory action in addition to its modulatory effect on
glucose and fatty acid metabolism. A large body of evidence
demonstrated that inhibition of transcription factors, such
as NF-kB, NF-AT, Sp1, and AP-1 by a PPARg is directly
responsible for attenuating proinflammatory cytokine pro-
duction (17-19). However, our results support that upregu-
lation of IL-10 may also be responsible for the anti-inflam-
matory effects of a PPARg. Although we did not provide a
direct causal link between IL-10 and other proinflammatory
mediators in this study, IL-10 might be critical in the protec-
tive mechanism, given that IL-10 has PPARg-activated recep-
tor response element (PPRE) promoter-specific for PPARs,
and that rosiglitazone has been shown to increase IL-10 pro-
duction from mature dendritic cells or CD4+ T cells (15).
Additionally, we also observed the IFN-g level increased mar-
kedly early after cisplatin injection. Interferon-g is a well-
known T cell cytokine that is known to play an important
role in tissue injury. Liu et al. (20) demonstrated the patho-
physiologic role of T lymphocytes by observing loss of pro-
tection in cisplatin nephrotoxicity in nu/nu mice by adoptive
transfer of T lymphocytes. Although they identified infiltra-
tion of CD3+ cells early after cisplatin administration, they
did not detect an increased IFN-g level. Our study showed
that IFN-g increased markedly early in cisplatin-treated kid-
neys and that rosiglitazone pretreatment significantly sup-
pressed IFN-g production. Discrepancy in tissue cytokines
and chemokines between experiments might come from using
animals of different strains, different doses of cisplatin, or sam-
ple timing. In the experiments of Liu et al. (20), they observed
that CD3+ cell infiltration peaked at 12 hr, returned to a
normal level at 24 hr, but they measured tissue cytokine lev-
els at 24 and 72 hr; and this timing might be too late for the
detection of cytokine production. Although we did not demon-
strate the morphologic evidence of T cell infiltration, increas-
ed production of IFN-g from T cells is likely to contribute
to the pathogenesis of cisplatin nephrotoxcity. The cisplatin-
induced tissue cytokine milieu that favors inflammation might
have ultimately led to substantial inflammation. We observed
an increased number of F4/80-positive kidney macrophages
and esterase-positive neutrophils 48 hr after cisplatin injec-
tion and also that rosiglitazone pretreatment markedly atten-
uated tissue inflammation. Neutrophils are thought to con-
tribute to tissue injury by releasing a variety of mediators.
And several anti-inflammatory strategies, which result in a
decrease in neutrophil infiltration, attenuated cisplatin-induced
kidney injury. The number of F4/80+ cells increased marked-
ly by cisplatin; and also rosiglitazone pretreatment signifi-
cantly reduced their infiltration. However, the role of F4/80
kidney macrophages in cisplatin nephrtoxicity is still unclear.
Recent study by Lu et al. (3) demonstrated that liposome clo-
dronate injection for the depletion of macrophages did not
attenuate cisplatin-induced kidney injury. 
Apoptosis is now recognized as an important mechanism
of cisplatin-induced renal injury. There are two major path-
ways that lead to apoptosis, both of which culminate in a
common death program. Signals from the mitochondrial and
death receptor pathways activate ‘‘initiator’’ caspases 9 or 8,
respectively, and this activation subsequently cleaves and acti-
vates ‘‘executioner’’ caspase 3 (5, 21, 22). Tsuruya et al. (22)
demonstrated direct involvement of the receptor-mediated
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apoptosis via activation of the mitochondrial pathway. How-
ever, the present study demonstrated that cisplatin-induced
activation of caspase 3 is mostly independent of caspase 8 or
9 activation and contribute to tubular cell apoptosis. Although
the upstream signal that led to direct activation of caspase 3
is not clear in this study, a variety of factors, such as direct
DNA damage, inflammatory mediators, or reactive oxygen
species are all likely to contribute to activation of caspase 3
and apoptotic cell death. Rosiglitazone pretreatment signif-
icantly reduced the activation of caspase 3 and apoptosis with-
out an effect on caspases 8 or 9, suggesting the independent
effect of rosiglitazone on caspase 3. Additionally, because in-
flammatory mediators also can induce tubular cell apoptosis,
rosiglitazone-induced IL-10 upregulation might also con-
tribute to decreased apoptosis. 
In conclusion, our study demonstrates rosiglitazone pre-
treatment protects mice from cisplatin nephrotoxicity. The
beneficial effect is thought to be mediated by upregulation
of endogenous IL-10 production by rosiglitazone with sub-
sequent reduction in tissue inflammation and cytotoxicity.
Rosiglitazone is currently clinically available for the treat-
ment of insulin resistance and its anti-inflammatory effect
can be used to prevent cisplatin nephrotoxicity in the treat-
ment of solid tumors. 
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